| [1] |
Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories[J]. Lancet, 2018,392:2052-2090.
|
| [2] |
Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012,379:815-822.
|
| [3] |
Eriksson D, Goldsmith D, Teitsson S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anemia[J]. BMC Nephrol,2016,17:97. doi: 10.1186/s12882-016-0312-9.
|
| [4] |
束金莲, 李贺, 姚少峰, 等. 初始血液透析患者贫血的相关危险因素回顾性研究[J]. 中国现代医学杂志, 2020:1-9.
|
| [5] |
Ni Z, Jin H, Jiang G, et al. A telemedicine-based registration system for the management of renal anemia in patients on maintenance hemodialysis: multicenter study[J]. J Med Inter Res, 2019,21:e13168.doi: 10.2196/13168.
|
| [6] |
McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease[J]. Am J Nephrol, 2013,37:549-58.
|
| [7] |
Semenza GL. HIF-1 and mechanisms of hypoxia sensing[Z]. England: Elsevier Ltd, 2001,13: 167-171.
|
| [8] |
Wang K, Wu J, Xu J, et al. Correction of anemia in chronic kidney disease with angelica sinensis polysac-charide via restoring EPO production and improving iron availability[J]. Front Pharmacol, 2018,9:803. doi:10.3389/fphar.2018.00803.
|
| [9] |
Schwartz AJ, Das NK, Ramakrishnan SK, et al. Hepatic hepcidin/intestinal HIF-2alpha axis maintains iron absorption during iron deficiency and overload[J]. J Clin Invest, 2019,129:336-348.
|
| [10] |
Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019,381:1011-1022.
|
| [11] |
Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator(darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan[J]. J Am Soc Nephrol, 2020,31:1628-1639.
|
| [12] |
Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis[J]. Nephrol Dial Transplant, 2021.doi: 10.1093/ndt/gfab051.
|
| [13] |
Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients[J]. Kidney Int Rep, 2021,6:624-635.
|
| [14] |
Shutov E, Sulowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)[J]. Nephrol Dial Transplant, 2021.doi: 10.1093/ndt/gfab057.
|
| [15] |
Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study[J]. J Am Soc Nephrol, 2021,32:737-755.
|
| [16] |
Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019,381:1001-1010.
|
| [17] |
Yang Q, Wang X. A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anemia[J]. Int J Clin Pract, 2021.doi: 10.1111/ijcp.14011.
|
| [18] |
Chen C, Yan S, Qiu S, et al. HIF/Ca2+/NO/ROS is critical in roxadustat treating bone fracture by stimulating the proliferation and migration of BMSCs[J].Life Sci,2021.doi: 10.1016/j.lfs.2020.118684.
|
| [19] |
Morris DR, Qu Y, Agrawal A, et al.HIF-1α modulates core metabolism and virus replication in primary airway epithelial cells infected with respiratory syncytial virus[J]. Viruses, 2020,12:1088. doi: 10.3390/v12101088.
|
| [20] |
Zhang X, Zhang Y, Wang P, et al. Adipocyte hypoxia-inducible factor 2alpha suppresses atherosclerosis by promoting adipose ceramide catabolism[J]. Cell Metab, 2019,30:937-951.
|
